HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Mahul B Amin Selected Research

Leiomyomatosis

11/2021Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors.
1/2021New developments in existing WHO entities and evolving molecular concepts: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
12/2018Clues to recognition of fumarate hydratase-deficient renal cell carcinoma: Findings from cytologic and limited biopsy samples.
5/2018Morphological clues to the appropriate recognition of hereditary renal neoplasms.
1/2018Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
1/2018SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
7/2017A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
11/2016Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
12/2015Emerging Entities in Renal Neoplasia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Mahul B Amin Research Topics

Disease

79Neoplasms (Cancer)
12/2023 - 02/2002
35Carcinoma (Carcinomatosis)
10/2022 - 02/2002
32Prostatic Neoplasms (Prostate Cancer)
05/2024 - 08/2002
29Renal Cell Carcinoma (Grawitz Tumor)
12/2023 - 04/2003
18Neoplasm Metastasis (Metastasis)
12/2023 - 02/2003
11Adenocarcinoma
10/2022 - 02/2002
9Leiomyomatosis
11/2021 - 12/2015
6Kidney Neoplasms (Kidney Cancer)
12/2023 - 06/2005
6Oxyphilic Adenoma (Oncocytoma)
10/2022 - 01/2005
5Urinary Bladder Neoplasms (Bladder Cancer)
11/2022 - 06/2010
4Noninfiltrating Intraductal Carcinoma (DCIS)
10/2022 - 01/2009
4Necrosis
01/2021 - 01/2005
4Squamous Cell Carcinoma (Epidermoid Carcinoma)
11/2020 - 11/2012
4Glandular and Epithelial Neoplasms (Neoplasms, Glandular)
11/2019 - 03/2002
4Medullary Carcinoma
01/2018 - 06/2005
3Small Cell Carcinoma
05/2023 - 01/2003
3Prostatic Intraepithelial Neoplasia
10/2022 - 09/2005
3Carcinoma in Situ
05/2020 - 05/2013
3Tuberous Sclerosis (Bourneville's Disease)
05/2018 - 09/2002
3Adenoma (Adenomas)
09/2008 - 06/2004
2Leiomyoma (Uterine Fibroids)
06/2012 - 04/2002
2Colorectal Neoplasms (Colorectal Cancer)
01/2010 - 01/2005
2Margins of Excision
09/2009 - 10/2008
2renal Oncocytoma
02/2009 - 06/2005
2Smooth Muscle Tumor
01/2009 - 04/2002
2Leiomyosarcoma
01/2009 - 04/2002
2Angiomyolipoma
05/2005 - 09/2002
2Transitional Cell Carcinoma
01/2003 - 02/2002
2Metaplasia
09/2002 - 04/2002
1Neuroblastoma
06/2023
1Inflammation (Inflammations)
05/2023
1Basal Cell Carcinoma (Rodent Ulcer)
10/2022
1Erectile Dysfunction
10/2022
1Ductal Carcinoma
10/2022

Drug/Important Bio-Agent (IBA)

15Keratins (Keratin)IBA
08/2014 - 02/2002
13Proteins (Proteins, Gene)FDA Link
01/2018 - 03/2002
10Biomarkers (Surrogate Marker)IBA
05/2023 - 12/2006
10Prostate-Specific Antigen (Semenogelase)IBA
01/2022 - 02/2002
10AntibodiesIBA
10/2016 - 04/2002
9Fumarate Hydratase (Fumarase)IBA
01/2022 - 11/2016
8AndrogensIBA
01/2023 - 02/2003
8Keratin-7 (Cytokeratin 7)IBA
07/2014 - 11/2003
6VimentinIBA
12/2023 - 02/2003
6alpha-methylacyl-CoA racemaseIBA
05/2020 - 06/2004
6Racemases and Epimerases (Epimerases and Racemases)IBA
01/2020 - 02/2005
6Uroplakin IIIIBA
07/2014 - 01/2003
5Succinate Dehydrogenase (Fumarate Reductase)IBA
11/2021 - 01/2015
5DesminIBA
06/2012 - 03/2002
4Keratin-20 (Cytokeratin 20)IBA
05/2020 - 01/2003
3Transcription Factors (Transcription Factor)IBA
06/2023 - 01/2005
3ChromatinIBA
01/2019 - 04/2002
3MucinsIBA
04/2018 - 01/2006
3DNA (Deoxyribonucleic Acid)IBA
01/2018 - 01/2003
3ThrombomodulinIBA
07/2014 - 01/2003
3Coenzyme A (CoA)IBA
12/2013 - 09/2005
3Cadherins (E-Cadherin)IBA
09/2012 - 10/2007
3Eosine Yellowish-(YS) (Eosin)IBA
09/2010 - 03/2002
3Hematoxylin (Haematoxylon)IBA
09/2010 - 03/2002
3OligonucleotidesIBA
02/2009 - 01/2003
2Cathepsin KIBA
12/2023 - 01/2012
2Docetaxel (Taxotere)FDA Link
01/2023 - 10/2019
2Inhibins (Inhibin)IBA
02/2022 - 04/2002
2Indicators and Reagents (Reagents)IBA
12/2021 - 05/2018
2Anaplastic Lymphoma KinaseIBA
01/2021 - 01/2009
2Phenobarbital (Luminal)FDA Link
01/2021 - 01/2021
2N 30IBA
07/2014 - 02/2009
2LipidsIBA
03/2010 - 05/2005
2Monoclonal AntibodiesIBA
01/2010 - 08/2002
2claudin 8IBA
02/2009 - 10/2007
2Formaldehyde (Formol)FDA Link
02/2009 - 05/2005
2ParaffinIBA
02/2009 - 01/2003
2EnzymesIBA
02/2009 - 01/2005
2Reactive Oxygen Species (Oxygen Radicals)IBA
12/2008 - 01/2005
2beta-DefensinsIBA
05/2005 - 04/2003
2ParvalbuminsIBA
02/2005 - 02/2003
1MTOR InhibitorsIBA
12/2023
1EverolimusFDA Link
12/2023
1TOR Serine-Threonine KinasesIBA
12/2023
1TransducinIBA
06/2023
1Immune Checkpoint ProteinsIBA
05/2023
1LigandsIBA
05/2023
1InterferonsIBA
10/2022
1Interleukin-10 (Interleukin 10)IBA
10/2022
1Interleukin-13IBA
10/2022
1trans-sodium crocetinate (crocetin)IBA
10/2022
1Interleukin-6 (Interleukin 6)IBA
10/2022
1Interleukin-23 (Interleukin 23)IBA
10/2022
1Interleukin-2 (IL2)IBA
10/2022
1MART-1 AntigenIBA
02/2022
1Calbindin 2IBA
02/2022
1RNA (Ribonucleic Acid)IBA
01/2022

Therapy/Procedure

23Therapeutics
12/2023 - 03/2002
13Radiotherapy
05/2024 - 01/2006
10Prostatectomy (Retropubic Prostatectomy)
01/2021 - 05/2002
7Cystectomy
04/2022 - 06/2010
4Nephrectomy
02/2019 - 01/2009
3Drug Therapy (Chemotherapy)
05/2023 - 10/2019
2Immunotherapy
05/2023 - 01/2021
2Nephroureterectomy
01/2020 - 05/2008
2Precision Medicine
01/2016 - 01/2010